Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia (Q85397077)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Physicians compliance during maintenance therapy in children with Down syndrome and acute lymphoblastic leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

lymphoblastic leukemia

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

C Bohnstedt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Levinsen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

B Zeller

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Taskinen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

S Hafsteinsdottir

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

H Björgvinsdóttir

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

M Heyman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

K Schmiegelow

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Nordic Society of Pediatric Hematology and Oncology (NOPHO)

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

9 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

866-870

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23138181%20AND%20SRC:MED&resulttype=core&format=json

Pattern of malignant disorders in individuals with Down's syndrome.

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Hematologic abnormalities in children with Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

The management of neoplastic disorders of haematopoiesis in children with Down's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Acute leukaemia in children with Down syndrome: a population-based Nordic study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Prognosis of Down's syndrome with acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Malignancy in children with trisomy 21.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Acute leukemias in children with Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Risks of leukaemia and solid tumours in individuals with Down's syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Down syndrome, drug metabolism and chromosome 21.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

The incidence peaks of the childhood acute leukemias reflect specific cytogenetic aberrations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Model-checking techniques based on cumulative residuals

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Advances in individual prediction of methotrexate toxicity: a review

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29--30, 2005

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

White-cell counts in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Hematological studies in children with Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

The human GARS-AIRS-GART gene encodes two proteins which are differentially expressed during human brain development and temporally overexpressed in cerebellum of individuals with Down syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Profound abnormality of the B/T lymphocyte ratio during chemotherapy for pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Insulin-like growth factor-I and insulin-like growth factor binding protein-3 during maintenance chemotherapy of acute lymphoblastic leukemia in children

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021

Leucocyte function in Down's syndrome and acute leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.325

7 January 2021